skip to Main Content
Get your free newsletter: Actionable insight each morning for self-directed investors. 
Home » Regular Columns » Three Quick Facts » Three Quick Facts: Restaurant Group, Oxford Biomedica and Oncimmune

Three things you need to know in the financial markets this morning from investment writer, Tony Cross.

The Restaurant Group

Interim results from The Restaurant Group [LON:RTN] are out this morning, covering the 26 weeks to end of June. Revenues were more than halved leaving the company to trade a £28.1m profit a year ago into a £47.5m loss. The trading portfolio has been dramatically reshaped too, but the note is keen to stress how sales have bounced back since lockdown restrictions were eased on July 4th. 90% of the retained estate is open with the pubs division doing exceptionally well in terms of market outperformance. There’s a lot of detail here but management state that even with the uncertainty of further restrictions, they now have a business that can deliver long term shareholder value.

Oxford Biomedica

There’s a note from Oxford Biomedica [LON:OXB] this morning stating that they have received regulatory approval for an additional manufacturing suite. This is the culmination of a doubling of capacity from a year ago and the facility will be dedicated to the manufacture of COVID-19 vaccines.

Subscribe for more stories like this, 8am weekdays - for free!

Oncimmune Holdings

There’s news from Oncimmune Holdings [LON:ONC] – the leading global immunodiagnostics group – that it has received UK government funding to help with better diagnosis of COVID-19 patients. The company is working on a ‘Validated research tool to be used to predict disease severity and individual therapeutic response to COVID-19 in aid of rapid vaccine and drug development’. The note doesn’t however appear to include any detail over the size of the funding which has been awarded.

Sign up for three quick facts and more with our Free Daily Digest newsletter, every weekday morning.

Please note this article does not constitute investment advice. Investors are encouraged to do their own research beforehand or consult a professional advisor.

Tony Cross

Tony Cross

Tony Cross is a market commentator with over 15 years of experience, producing compelling, insightful copy for journalists and investors alike. Focusing on macroeconomics, UK blue chip equities and inter market analysis, Cross's commentary is well regarded for its clarity and ability to cut through the waffle. He has been quoted in publications as diverse as The Financial Times, The Times, The Guardian and The Sun. He has also been a regular guest on both Share Radio and TipTV.

Stocks in Focus

Here are some of the smaller companies we are following most closely. They all represent significant growth stories in our view. Our in-depth reports go into more detail on why we like them.


Subscribe for more stories like this, 8am weekdays - for free!

Get your free daily newsletter: 

Thanks to our Partners

Our partners are established, regulated businesses and we are grateful for their support.

FP Markets
Back To Top